Outset Medical Inc (NASDAQ:OM) shares changed 12.57% today on 895,826 shares – compared to the 30 day average of 385,886 shares traded.
After today’s close at $14.74 the company has a 50 day moving average of $18.91.
The company anticipates its next earnings on 2022-11-02.
Outset Medical is down 63.42% so far this year.
For technical charts, analysis, and more on Outset Medical visit the company profile.
About Outset Medical Inc
Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.
To get more information on Outset Medical Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Outset Medical Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Fix from Equities News to receive the best stories to your inbox.
Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.
Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.
The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer